Is China’s biotech boom at risk? Fear of policy backlash after death in gene-editing trial

The death of a six-year-old girl after receiving an experimental gene-editing therapy has been described by scientists as a tragedy that highlights the need to improve trial safeguards. But some in the biotechnology industry fear Chinese policymakers may curtail the regulatory flexibility that scientists have…